Hubei Honest Biochemical Co., Ltd.

Quick Details

Alias: Proscar;Propecia

Finasteride CAS NO.: 98319-26-7

Molecular Formula: C20H24O2

Molecular weight: 372.54

Assay: 99%min

Appearance:white crystalline solid

Usage: for the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB)

Description:

Finasteride: Proscar; Prostide; Raw Powder; Baldness Treatment; Treat Hair Loss; Pharmaceutical Raw Materials

Finasteride is a popular anti-androgen medication manufactured by Merck most commonly known as either Proscar or Propecia. Based on the progesterone skeleton, Finasteride belongs to a class of medications known as 5alpha-reductase inhibitors and as such is used for the treatment revolving around type 2 5-AR based occurrences.

This is important for performance enhancers as DHT based anabolic steroids have specific side-effects that may occur that can largely be remedied with the use of a 5-AR inhibitor such as Finasteride.

As a type 2 5-AR inhibitor Finasteride was designed for the purpose of treating hair-loss, prostate enlargement, as well as prostate cancer.

Finasteride is very common among those who supplement with anabolic steroids yet fear hair-loss but there are important things you need to understand before you consider Finasteride use. As an androgen suppressor Finasteride can seriously inhibit the gains made while on cycle, severely and on that basis it is not highly recommended for on-cycle hair preservation.

Propecia (finasteride) is used to treat male pattern baldness (androgenic alopecia) in men. Topically (on the scalp itself) it is of some effect in minimizing further hair loss. In combination with Nizoral and spironolactone (which smells awful, by the way) it can actually reverse loss moderately.

Used for the treatment of prostate disease first. Clinical studies suggest that, with finasteride 1 mg/day, continuous oral 3 months or slightly long can have hair growth, after continuous treatment 1 year hair growth rate to 48%, and can continue to fall off, taking the hair organization 2 years hair growth rate reached 66% ~ 83%.

Applications:

Finasteride belongs to a class of medications known as 5alpha-reductase inhibitors and as such is used for the treatment revolving around type 2 5-AR based occurrences.

Medical uses:

(1) Benign prostatic hyperplasia:

Physicians use finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate. The FDA-approved dose is 5 mg once a day. Six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment. If the drug is discontinued, any therapeutic benefits reverse within about 6–8 months. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.

(2) Male pattern baldness:

Three Phase 3 clinical trials examined the efficacy of finasteride in the treatment of mild to moderate male pattern baldness. The primary endpoints of each trial were hair count and user self-assessment. Secondary endpoints included investigator assessment and examination of scalp photographs. Each patient also filled out questionairres regarding sexual health and non-scalp body hair growth. These trials enrolled 1879 men and had a duration of one year. Of these 1879 men, 1215 elected to participate in a one year double blind extension trial. Additional extension trials were performed such that 323 men experienced over 4 years of treatment.

Across all three trials, at one year men taking Propecia had 107 more hairs per 1 inch diameter section of scalp (in the area affected by hair loss) than men treated with placebo. At two years the difference was 138 hairs. Maximum hair gain occurred during the first two years, but because hair loss was more rapid in the placebo treated group, the difference between treated and placebo groups increased to 277 hairs per inch circle at 5 years. Self assessment showed that treated patients perceived an improvement in hair density and overall appearance. These results were supported by investigator ratings and by independent readers examining scalp photographs.

At the end of the first year, the sexual health questionaire revealed differences in sexual interest, erections, and perception of sexual problems that favored the placebo group. However, no significant difference was seen in the question on overall satisfaction with sex life.